Drug Profile
Research programme: checkpoint kinase 1 inhibitors - CRT/Sareum/ICR
Alternative Names: CHK1 inhibitors - CRT/Sareum/ICRLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cancer Research Technology; Sareum; The Institute of Cancer Research
- Class Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 04 Feb 2011 Research programme: checkpoint kinase 1 inhibitors - CRT/Sareum/ICR is available for licensing as of 30 Nov 2010. http://www.cancertechnology.co.uk
- 22 Nov 2007 Preclinical development is ongoing